Kim Brown is the AAPS communications and social media manager in the Public Outreach Department.
With the holiday season nearing, many people have already started making travel plans. However, one thing that puts a damper in traveling is motion sickness, which affects 33 percent of people in mild circumstances and 66 percent of people in severe conditions.
Relief may be around the corner for those susceptible to motion sickness through a new prototype for medicated chewing gum that may offer advantages over conventional oral solid dosage forms. This research was presented today at the 2012 AAPS Annual Meeting and Exposition.
Lead researcher Mohsen Sadatrezaei, RoshaDarou Co., and a team of researchers from the Islamic Azad University School of Pharmaceutical Sciences in Tehran, Iran, have developed a medicated gum that will improve patient compliance and faster absorption through the cheek, which will alleviate motion sickness sooner.
To learn more about this exciting new research, view the team’s abstract, no. W4119, in the 2012 AAPS Annual Meeting and Exposition MyAgenda Planner.